Intelligence · Clinical Development
Pipeline search results
Programs matching “Novartis” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 341 pipeline programs matching "Novartis" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
rapcabtagene autoleucel
Novartis Pharmaceuticals
Scleroderma, Diffuse
1 trial -
zigakibart
Novartis Pharmaceuticals
Immunoglobulin A Nephropathy (IgAN)
1 trial -
68Ga-NNS309
Novartis Pharmaceuticals
Pancreatic Ductal Adenocarcinoma
1 trial -
A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers
Novartis Pharmaceuticals
Advanced high-grade serous ovarian cancer (OC), Locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma (NSCLC)
1 trial -
CAAA601A52101
Novartis Pharmaceuticals
Glioblastoma
1 trial -
CAAA603C12101
Novartis Pharmaceuticals
Glioblastoma
1 trial -
CAAA617A12101
Novartis Pharmaceuticals
Metastatic Castration-Resistant Prostate Cancer
1 trial -
CADPT01C12101
Novartis Pharmaceuticals
Advanced or metastatic BRAF V600 colorectal cancer.
1 trial -
CAIN457E22101
Novartis Pharmaceuticals
Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA)
1 trial -
CDAK539A12102
Novartis Pharmaceuticals
Patients with advanced malignancies
1 trial -
CDAK539A12103
Novartis Pharmaceuticals
Advanced Malignancies and Hepatic Impairment
1 trial -
CDFF332A12101
Novartis Pharmaceuticals
Advanced, relapsed Clear Cell Renal Cell Carcinoma
1 trial -
CDKY709A12101C
Novartis Pharmaceuticals
Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma
1 trial -
CDLX313A12101
Novartis Pharmaceuticals
Parkinson’s Disease
1 trial -
CEGF816X2102
Novartis Pharmaceuticals
Patients with EGFR-mutant Non Small Cell Lung Cancer
1 trial -
CFKL480A02101
Novartis Pharmaceuticals
Advanced breast cancer and advanced NSCLC
1 trial -
CFXX489A12101
Novartis Pharmaceuticals
Locally advanced or metastatic unresectable colorectal cancer (CRC), Locally advanced unresectable or metastatic breast cancer (BC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)
1 trial -
CGCJ904A12101
Novartis Pharmaceuticals
Locally advanced unresectable or metastatic colorectal cancer (CRC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic soft tissue sarcoma (excluding GIST and Kaposi sarcoma), Locally advanced unresectable or metastatic HR+/HER2- ductal or lobular breast cancer (BC), Locally advanced unresectable or metastatic triple negative breast cancer (TNBC)
1 trial -
CHJB647A02101
Novartis Pharmaceuticals
Heart failure (HF)
1 trial -
CIAG933A12101
Novartis Pharmaceuticals
Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway
1 trial -
CIDH305X2101
Novartis Pharmaceuticals
Advanced malignancies that harbor IDH1R132 mutations
1 trial -
CINE963A02103
Novartis Pharmaceuticals
Malaria
1 trial -
CKFA115A12101
Novartis Pharmaceuticals
Thymic Carcinoma, Nasopharyngeal Cancer, Anal Cancer, Head and Neck Squamous Cell Carcinoma, Epithelial Ovarian Cancer, Cutaneous melanoma, Mesothelioma, Non-small cell lung cancer, Esophagogastric Cancer, Triple negative breast cancer, Microsatellite Instability High Colorectal Cancer, Clear Cell Renal Cell Carcinoma
1 trial -
CLDK378A2120C
Novartis Pharmaceuticals
Non-small cell lung cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.